MRK · Merck & Co Inc
Price
Snapshot
50 fields · last close| Market Cap | $356.0B |
| P/E | 112.20 |
| Float | 2.47B |
| Beta | 0.12 |
| Volatility | 5.0% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Mega cap |
| Macro sensitivity | Low |
| Clavix score | 74.7 |
| Price | 144.30 |
| Change | +0.00% |
| Prev Close | 144.30 |
| Open | 143.77 |
| Day Low | 142.73 |
| Day High | 144.35 |
| Avg Vol | 9 |
| Avg $ Vol | $1.32B |
| 52W High | 156.92 |
| 52W Low | 82.01 |
| 52W Pos | 83.2% |
| From High | −8.04% |
| From Low | +75.95% |
| Max DD 1Y | −11.90% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | −1.81% |
| SMA 50 | +1.41% |
| SMA 200 | +17.45% |
| RSI (14) | 46.3 |
| Vol 30D | 23.6% |
| Vol 90D | 32.9% |
| 1Y Range | 82–157 |
| Daily bars | 526 |
| Perf Week | −3.01% |
| Perf Month | −4.84% |
| Perf Quarter | +13.82% |
| Perf Half Y | +19.38% |
| Perf Year | +60.10% |
| Perf YTD | +35.56% |
| Prev Day | +0.00% |
| Clavix | B+ |
| Debt / Eq | 0.34 |
| Curr Ratio | 1.54 |
| Int Cover | 0.4× |
| FCF Margin | 19.0% |
| Rev Growth | +1.3% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 9 / 14 |
What MRK does
Merck & Co., Inc. operates as a healthcare company worldwide.
It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets.
The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Clavix risk grade
regraded every trading dayMRK grades B+, 74.7 of 100. Steadiest on Macro Resilience (66), most exposed on News Sentiment (23, weak). 0 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 9 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| MRK | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.12 | 0.42 |
| Volatilityannualized | 5.0% | 10.6% |
| Max drawdown, past yearworst peak-to-trough fall | −11.9% | — |
| Typical daily movemedian absolute daily change | 1.03% | — |
| Days beyond ±3%of the last 252 sessions | 20 (8%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MRK | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.12 | 0.42 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MRK | |
|---|---|
| 1 week | −3.0% |
| 1 month | −4.8% |
| Year to date | +35.6% |
| 1 year | +60.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MRK | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 18 Sep |
| Average score0 most bearish, 100 most bullish | 66 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 3 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| MRK | |
|---|---|
| Revenue growthyear over year | +1.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openMerck announced on October 1, 2026 that its experimental drug tulisokibart met its Phase 2b efficacy goals in patients with moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition. The company said the results support moving the program into Phase 3 trials.
BMO Capital Markets said it is more confident in Merck's plan to replace revenue that will be lost when its top drug Keytruda loses patent protection than in Bristol Myers Squibb's plan to offset revenue losses when its drugs Opdivo and Eliquis lose exclusivity.
Moderna and Merck are jointly developing a personalized mRNA cancer vaccine that could tap into a market worth several billion dollars, but some Wall Street analysts have raised concerns that the companies' valuations may be running ahead of what the product can realistically deliver.
Merck reported phase 2b study results for its drug tulisokibart in hidradenitis suppurativa (a chronic, painful inflammatory skin condition causing abscesses and scarring), and UBS Securities said the data looks solid. The article body was truncated, so further details are unavailable.
An analyst piece compares JNJ and MRK, noting both stocks have surged in 2026, and argues that MRK's dividend faces a reckoning due to a looming patent cliff and a balance sheet loaded with acquisition debt, while JNJ's is more durable. No specific new event or filing at MRK is reported.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | A- | $617.0B | 29.33 | 0.20 | Compare |
| AZN | AstraZeneca PLC | B+ | $186.6B | 23.65 | 1.38 | Compare |
| PFE | Pfizer Inc | A- | $158.5B | 36.57 | 0.31 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $124.9B | 13.46 | 0.19 | Compare |
| LLY | Eli Lilly and Co | B | $1.08T | 40.28 | 0.42 | Compare |
| RPRX | Royalty Pharma PLC | A | $32.87B | 40.33 | 0.39 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 11.22 | 0.71 | Compare |
| VTRS | Viatris Inc | B+ | $20.35B | — | 0.90 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.